NUZ — Neurizon Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$56.62m
- AU$46.50m
Annual income statement for Neurizon Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.12 | 3.67 | 4.51 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 3.88 | 3.45 | 4.2 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.37 | 4.93 | 6.13 | 1.65 | 8.92 |
| Operating Profit | -1.24 | -1.26 | -1.62 | -1.65 | -8.92 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.36 | -1.34 | -1.71 | -1.57 | -8.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.36 | -1.34 | -1.71 | -1.57 | -8.9 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.36 | -1.34 | -1.71 | -6.21 | -7.67 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.36 | -1.34 | -1.71 | -6.21 | -7.67 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.005 | -0.004 | -0.005 | -0.008 | -0.018 |